Insulin and glucagon secretory responses to arginine, glucagon, and theophylline during perifusion of human fetal islet-like cell clusters.
The secretory responsiveness of human fetal pancreatic endocrine cells was studied by perifusion of cultured islet-like cell clusters (ICC). ICC were obtained from 7 fetuses at 13-15 weeks gestation and 21 fetuses at 17-22 weeks gestation. The ICC were challenged with glucose (20 mmol/L), arginine (10 mmol/L), glucagon (1.4 mumol/L), and theophylline (10 mmol/L) combined with zero, low (2 mmol/L), or high (20 mmol/L) glucose. At 13-15 weeks, glucose and arginine enhanced insulin release in some experiments, whereas glucagon and theophylline were always potent stimuli (mean response, 4-fold regardless of the glucose concentration). At 17-22 weeks, both glucose alone (20 mmol/L) and arginine (10 mmol/L, with 2 mmol/L glucose) induced a small (1.4- to 1.5-fold) increase in insulin release. When arginine was combined with 20 mmol/L glucose, the response was potentiated to become a 2.3-fold increase. In contrast, glucagon was equally effective in 2 and 20 mmol/L glucose (2.9- and 2.6-fold responses, respectively) and produced a half-maximal response even in the absence of glucose. In this age range the most potent stimulus for insulin release was clearly theophylline. The effect of theophylline was also remarkably independent of the glucose concentration of the perifusate (5.6-, 8.1-, and 8.6-fold responses at 0, 2, and 20 mmol/L glucose, respectively). Glucagon release from the ICC of the 17- to 22-week-old fetuses was low (mean basal glucagon release, 2.9; insulin, 24.8 fmol/100 ICC/min). Glucagon release was not affected by 20 mmol/L glucose, but was stimulated by arginine and theophylline. These findings suggest that in the fetal pancreas, in contrast to the adult organ, insulin release results from elevation of intracellular cAMP concentrations (by glucagon or theophylline) relatively independent of the exogenous glucose concentration. Therefore, glucagon may have an important role in regulating insulin release during the early development of human fetal B-cells.
D001120:Arginine / Q000494:pharmacology; D002478:Cells, Cultured; D005333:Fetus / Q000378:metabolism; D005865:Gestational Age; D005934:Glucagon / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000196:embryology* / Q000378:metabolism; D010477:Perfusion; D013806:Theophylline / Q000494:pharmacology
D007328:Insulin; D005934:Glucagon; D001120:Arginine; D013806:Theophylline